Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Releases Earnings Results, Beats Estimates By $0.09 EPS

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) released its quarterly earnings data on Tuesday. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.09, Zacks reports. Swedish Orphan Biovitrum had a return on equity of 17.72% and a net margin of 4.74%.

Swedish Orphan Biovitrum Stock Performance

Shares of OTCMKTS:BIOVF remained flat at $45.72 during midday trading on Tuesday. The stock had a trading volume of 82 shares, compared to its average volume of 1,109. The company has a market cap of $16.27 billion, a PE ratio of 101.59 and a beta of 0.47. Swedish Orphan Biovitrum has a 1-year low of $34.88 and a 1-year high of $49.03. The business has a 50 day moving average of $46.31 and a two-hundred day moving average of $43.98. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 0.20.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BIOVF. Nordea Equity Research downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, October 22nd. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Finally, Pareto Securities lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.

Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.